Takeda Pharmaceutical Co. Ltd. Release: Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori

Tokyo/Osaka, Aug 31, 2012 (JCN Newswire) - Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka; President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) announced today that they have submitted a joint application* to Japan's Ministry of Health, Labour and Welfare seeking approval of Helicobacter pylori ("H. pylori") gastritis as an additional indication for H. pylori eradication by concomitant therapy with four proton pump inhibitors?lansoprazole, omeprazole, rabeprazole sodium and esomeprazole magnesium hydrate-manufactured and marketed by the four companies in Japan under five brand names. This concomitant therapy consists of a proton pump inhibitor, amoxicillin hydrate (generic name; marketed under two brand names), and either clarithromycin (generic named: marketed under two brand names) or metronidazole (generic name; marketed under one brand name).